Behind this search is almost always a tolerability question: someone wants an amount between two labeled steps to get through a rough stretch. The approved pen offers no such amount, and its instructions for use say not to set a dose by counting clicks. Prescribers manage a difficult titration with time and scheduling instead.
The question underneath the search
Nobody looks for a click chart out of curiosity about hardware. They look because week two of a new step went badly, or because a refill is late and the next pen is not in hand. Framed that way, the request is reasonable and the proposed solution is the problem.
Where someone fills that prescription affects how late a refill runs. Endocrinology clinics, manufacturer pharmacies like NovoCare and LillyDirect, and telehealth names such as Hims and Hers, Henry Meds, and HealthRX all handle resupply differently, and a provider page for Ozempic will usually spell out shipping cadence and what a lapse costs. That detail matters more during a hard titration than the headline price does.
An improvised intermediate amount is unmeasured. It cannot be recorded, cannot be repeated reliably, and cannot be interpreted later when someone tries to work out whether a symptom came from the drug or from the amount of it. Titration is a sequence of controlled observations, and an unknown quantity in the middle of that sequence erases the information the sequence was meant to produce.
What the labeled sequence actually is
Semaglutide for type 2 diabetes has a fixed published path. Treatment begins at 0.25 mg once weekly for four weeks, an amount the labeling describes as an initiation step rather than one intended for glycemic control. After four weeks it moves to 0.5 mg weekly. Further increases to 1 mg and then to 2 mg are each permitted only after at least four weeks at the preceding amount, and 2 mg once weekly is the maximum recommended dosage.
| Labeled step | Minimum time before an increase | Available on the pen? |
|---|---|---|
| 0.25 mg weekly | 4 weeks | Yes, on the 2 mg/3 mL presentation |
| 0.5 mg weekly | At least 4 weeks | Yes, on the 2 mg/3 mL presentation |
| 1 mg weekly | At least 4 weeks | Yes, on the 4 mg/3 mL presentation only |
| 2 mg weekly | Maximum recommended dosage | Yes, on the 8 mg/3 mL presentation only |
| Any amount between these | Not defined | No, the selector does not stop there |
The last row is the one that answers the search. A given presentation permits only its own steps, so the device cannot produce a half step even if someone decides they want one. Moving from 0.5 mg to 1 mg means a different pen, dispensed on a prescription, not a different way of turning the same one.
Why the interval is the real variable
The four-week intervals in the labeling are minimums, not deadlines. That distinction does most of the work in practice. GLP-1 receptor agonists slow gastric emptying and act on receptors involved in nausea and satiety, so the therapeutic effect and the unwanted one share a mechanism and scale together. Adaptation happens, but it takes weeks, and the weeks are the thing that can be adjusted.
A randomized open-label trial published in Diabetes Care compared a gradual titration approach with a standard one and reported better treatment adherence and fewer adverse events with the slower ramp. That is the evidence-backed version of what people are trying to improvise: not a smaller amount, more time at an amount the device can actually deliver.
The levers a prescriber has
There are more of them than most patients assume, and none require a chart. Staying at the current step past the four-week minimum is routine. Returning to the previous step and re-attempting the increase later is routine. Adjusting a concomitant insulin or sulfonylurea, since combination therapy shifts hypoglycemia risk and the semaglutide is not always the agent that should move. Managing hydration, since volume depletion from vomiting or diarrhea is what turns a tolerability problem into a kidney one.
Real-world persistence data underline why this matters. A United States claims analysis of once-weekly semaglutide found substantial discontinuation over the first year, concentrated early. People who leave in the first two months are rarely leaving because the drug failed. They leave because a week was intolerable and nobody had told them that pausing the schedule was an option.
Access route changes how fast that conversation happens
The practical question is who answers on a Tuesday when the second dose at a new step goes badly. Manufacturer channels such as NovoCare Pharmacy and LillyDirect handle dispensing but not clinical management. Endocrinology and primary care practices manage it well and often slowly. Published cash prices from telehealth programs including Ro, Hims and Hers, LifeMD, and formblends.com differ mainly in what the monthly figure includes, and whether a mid-titration message costs extra is a more useful comparison than the headline number.
A program that bills per consultation creates a quiet incentive not to call. During a titration window that incentive points in exactly the wrong direction.
Compounded preparations have no schedule to copy
Everything above describes an FDA-approved product with a fixed concentration and a labeled device. Compounded semaglutide is not FDA-approved, its concentration is set by the compounding pharmacy, and FDA has published its concerns about unapproved versions of these drugs sold for weight loss. No published escalation schedule exists for a compounded vial, and the milligram figures from a branded label do not carry over to one.
Where product expectations diverge
Ozempic is approved for type 2 diabetes in adults, with additional approved uses for cardiovascular risk reduction and for slowing kidney function decline in that population. Wegovy is the semaglutide product approved for chronic weight management, and its injection labeling runs a longer path to a usual maintenance dosage of 2.4 mg once weekly, titrating every four weeks. Applying one product’s expectations to the other produces steps that do not exist in the prescription actually held.
Both carry a boxed warning about thyroid C-cell tumors observed in rodents, and both are contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or with multiple endocrine neoplasia syndrome type 2.
Frequently asked questions
Is there an approved half step between 0.5 mg and 1 mg?
No. The labeled steps for the diabetes product are 0.25, 0.5, 1, and 2 mg once weekly, and each pen presentation supports only its own. An amount between them has no labeled interval, no accuracy testing behind it, and no way to be recorded meaningfully.
Does staying longer at one step reduce the eventual result?
Not in a way that shows up over months. Reaching a workable amount later costs little compared with stopping entirely during a bad week. Trial evidence on gradual titration points the other way, toward better adherence and fewer adverse events when the ramp is slowed.
Does everyone need to reach the maximum?
No. The higher steps exist for people who need additional glycemic control, not as a target in themselves. Someone meeting their goal at an earlier step has no built-in reason to keep climbing, and whether to do so is a prescriber decision rather than a default.
What should be reported between visits?
Vomiting that prevents keeping fluids down, symptoms that keep worsening rather than settling, severe abdominal pain, and any hypoglycemia in someone also taking insulin or a sulfonylurea. Those change the plan, and they change it faster than waiting for a scheduled appointment allows.
